Extending men's lives with radiotherapy for advanced prostate cancer

Extending men's lives with radiotherapy for advanced prostate cancer

Every year, around 7,000 men in the UK are diagnosed with advanced prostate cancer. For years, researchers have been investigating whether treating the prostate with radiotherapy could still help men after the cancer had spread elsewhere in the body. To explore this, researchers leading the large multi-arm clinical trial, STAMPEDE, introduced a new arm to test a key question: could adding radiotherapy to the still help men, even if the cancer has spread? Researchers also set out to discover which men might benefit most from adding radiotherapy to the standard treatment once the cancer has spread.

In STAMPEDE, one group of men received the standard treatment — hormone therapy and chemotherapy (docetaxel). A second group of men received the same treatment, with the addition of radiotherapy to the prostate.

After three years of follow-up, the initial results showed no difference in how long men lived between the two groups, suggesting that once the cancer had spread, adding radiotherapy to the standard treatment did not help men with advanced prostate cancer live longer.  However, through your support, Prostate Cancer UK funded a team at the Belfast-Manchester Movember Centre of Excellence to analyse the results in more detail. The team analysed bone scans taken from the men who had participated in the STAMPEDE trial. In total they collected and analysed over 7,000 scans from 140 hospitals.

The team found that men whose prostate cancer had spread to four or fewer places saw a clear benefit from adding radiotherapy. For this group of men, treating the prostate with radiotherapy alongside standard treatment helped them live longer than men receiving standard treatment alone.

After three years, 81% of men whose cancer had spread to four or fewer places and who were treated with radiotherapy were still alive, compared to 73% of men who received the standard treatment alone. This means that, for every 100 men treated, adding radiotherapy resulted in eight more men being alive after three years. 

202404 Ideas To Innovation Research Event Rosie Lonsdale 34
Professor Noel Clarke
“It’s a special feeling when your team discover something new that makes a difference. Thousands of patients around the world now have treatment which benefits them, which they would otherwise not have had.”
Professor Noel Clarke
20211210 Kevin Webber Dessert
Kevin Webber

Kevin Webber was diagnosed with advanced prostate cancer in 2014 and given just two years to live. After receiving radiotherapy, he has continued to defy expectations—raising close to a million pounds for Prostate Cancer UK through epic endurance challenges around the world, while inspiring many others to support the cause.

You can read more about Kevin’s journey and ongoing fight against prostate cancer on his personal blog.

I’m so glad I had the radiotherapy, because I now know that for men in my situation, where the cancer had spread, but not to too many sites, it’s a fantastic thing to do. So for me, research like this is absolutely amazing, because that’s how we find out about these new treatments. And along with the work behind the scenes to get these made available to men, that can make such a big difference. It’s why I want to keep on raising money so that these brilliant researchers can keep doing what they do best, and saving men’s lives.
Kevin Webber, based in Surrey

From research idea to access for all

 

Impact Idea

Idea

Researchers wanted to know whether adding radiotherapy to the standard treatment once prostate cancer had spread could still benefit men. They also wanted to find out if treating the prostate at this stage was too late to make a difference. This question was explored as part of the large trial called STAMPEDE

Impact Research

Lab research

A team of researchers based at the Manchester-Belfast Movember Centre of Excellence analysed bone scan images from men treated with radiotherapy. The team looked to see if there was a link between the number of sites the cancer had spread to and the benefit gained from radiotherapy treatment.

 

Impact Trials

Clinical trial

The team showed that men whose cancer had spread to four or fewer places benefited from radiotherapy. This group of men lived longer when their prostate was treated with radiotherapy, compared to men who received standard treatment alone.

Thanks to the image analysis performed by our researchers a simple bone scan, used in every hospital, can be used to predict a positive response to radiotherapy to the prostate.

Impact Approved

Approved for use

A second team funded by Prostate Cancer UK analysed data from the STAMPEDE trial and a second large European trial that also looked at radiotherapy after the prostate cancer had spread. This independent analysis concluded that radiotherapy should be considered for men whose cancer has spread to four or fewer places

Impact Access

Access for all

Work supported by these two Prostate Cancer UK grants provided the evidence NICE needed to update clinical guidelines. Adding radiotherapy to the standard treatment for men whose prostate cancer has spread is now standard clinical practice in the UK. This analysis has also helped shape clinical care in the United States of America and Europe. Thanks to your support, our funded researchers have helped men with prostate cancer live longer across the world.

What's next?

We continue to fund projects to improve the way radiotherapy treatment is given — to cure more men and do less harm. We’ve also funded projects that use smarter data to understand which men will benefit most from radiotherapy.

201905 Dr Ananya Choudhury 2

Read more

A test to help men choose between surgery and radiotherapy

Find out more
Bill Nailon

Read more

Identifying factors that can predict men’s response to radiotherapy

Find out more
Emma Hall Headshot Standard

Read more

A clinical trial to test a rapid form of radiotherapy

Find out more

Help us fund more lifesaving research like this...

With your continued support you can help us cure more men with less harm. Take action today and help us work towards a future where men's lives aren't limited by prostate cancer

Get Involved